Bruce Culleton, MD

CEO of ProKidney Corp.

Education

Bachelor's degree in Medical Science and a Doctor of Medicine degree from Memorial University of Newfoundland; MBA from Northwestern University, Kellogg School of Management.

Field of Expertise

Healthcare & Life Sciences - Medicine

Born

January 1, 1967 - 58 years ago

Economy Sector

Healthcare

Current Tenure

1 year 4 months (Nov 2023 - Present)

Previous Experience

Vice President and General Manager of CVS Kidney Care, LLC; Vice President and Chief Medical Officer at CVS Kidney Care; Vice President, Global Clinical Development at Becton, Dickinson and Company; Vice President, Renal Therapeutic Area at Baxter International Inc.

Bruce Culleton, MD, is the newly appointed CEO of ProKidney Corp., having taken over the role on November 15, 2023. He brings over 20 years of experience in kidney health from both industry and academia. Before stepping into the CEO position, Dr. Culleton was the Executive Vice President of Clinical Development and Commercialization at ProKidney. He's also held significant roles at CVS Kidney Care and Becton, Dickinson and Company, where he made key contributions to their kidney-focused advancements. His educational background is solid—a Bachelor's degree in Medical Science, a Doctor of Medicine, and an MBA from Northwestern University's Kellogg School of Management. As CEO, he earns a base salary of $625,000 with performance bonuses that aim to align with corporate achievements. Outside his professional life, Dr. Culleton is known for his commitment to improving kidney care, which is a key mission of ProKidney Corp.

Year

2023

Total Compensation

$366.68K

Salary

$244.96K

Board Justification

The compensation program is designed to attract, retain, and motivate senior management leaders capable of advancing the company's mission and strategy, rewarding them in alignment with financial performance and equity ownership.

Bonus

$120.82K

Board Justification

Cash bonuses earned by the named executive officers pursuant to our Non-Equity Incentive Compensation Plan for performance, with a corporate goal achievement of 59.8%.

Other

$891.00

Board Justification

Represents all other compensation paid to Dr. Culleton including insurance premiums with respect to a group life insurance policy, a group short-term disability policy, a group long-term disability policy, an accidental death and dismemberment policy, and flexible spending accounts.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as per the provided data.

Performance Metrics

Performance metrics for the CEO's compensation in 2023 were based on corporate goal achievements.

Tim Bertram, Ph.D.

Ex-CEO of ProKidney Corp.

June 2021 - November 2023